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ABSTRACT 
This article deals with Yemen’s current pharmaceutical scenario and possible future 
challenges that it may face.  The manuscript provides an overview of health services 
particularly pharmaceutical services and the critical health challenges facing the people of the 
country.  Details included are statistical data with regard to the health of the Yemeni 
population and their demographic backgrounds following administrative issues, policy for the 
medicinal trade and production, the regulation and financing.  The manuscript also deals with 
the government’s action about medicines, their procurement, and distribution in the public 
sector, and the public perception of medicines. Rational use of medicines is determined by the 
knowledge and attitude of the consumers. Future challenges are also anticipated. World health 
systems have been facing an incredible transformation to address new challenges with regard 
to the demographics, disease trends, the emergence and the re-emergence of diseases along 
with higher costs of health care delivery. This has led to a comprehensive review of health 
systems and how they function to serve the masses.  Some health systems do not seem to 
adequately provide services that really matter to the people and some deteriorate, following 
governments’ lack of efficiency in supporting and extending the services.  Other issues can 
also affect the ability of the health systems to deliver including health administration, 
healthcare financing, the lack of balance of the human resources, inaccessible and poor 
quality services and the impact of modifications and reform prevalent in other economic 
areas.  
 
Introduction  
 
Yemen has not been able to escape the many chronic diseases 
that have also plagued other Arab countries and the 
developing world in other regions.  It has been known to have 
high incidence of both communicable diseases (malaria, 
tuberculosis, schistosomiasis, sexually transmitted diseases 
and vaccine-preventable diseases) and non-communicable 
diseases (such as cardiovascular diseases, renal problems, 
cancer, and eye diseases). As if this is not enough, Yemen also 
displays certain factors of lifestyle that can pose risks or are 
hazardous to the people (the factors include tobacco use, ‘qat’ 
chewing, malnutrition, injuries and accidents) and inadequate 
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necessary sanitation (especially water sanitation). 
Unfortunately these are steadily increasing. 
The health situation in Yemen is acknowledged as the least 
favourable in the world.  Low birth weight has been known as 
one of the leading contributors to Yemen’s very high infant 
and under-five mortality rates The causes for this are three-
fold- poverty, closely-spaced pregnancies and low health 
awareness.  High fertility rate is also another issue among 
Yemeni women.  Higher fertility would add more pressure on 
a woman’s body and thus, they run the risk of being subject to 
potential death, or mortality.  Of course, this is exacerbated by 
the fact that Yemen is poor in resources and being over-
populated this would definitely be a big issue to address. 
 
Table 1: The basic indicators of healthcare in Yemen 
43 Under-5 mortality rank  
125 Under-5 mortality rate (U5MR), 
1990  
60 Under-5 mortality rate (U5MR), 
2012 
64 U5MR by sex 2012, male  
56 U5MR by sex 2012, female  
88 Infant mortality rate (under 1), 
1990  
46 Infant mortality rate (under 1), 
2012  
27 Neonatal mortality rate 2012  
23852,4 Total population (thousands) 2012  
752,2 Annual no. of births (thousands) 
2012  
43 Annual no. of under-5 deaths 
(thousands) 2012  
1110 GNI per capita (US$) 2012  
62,9 Life expectancy at birth (years) 
2012  
65,3 Total adult literacy rate (%) 2008-
2012*  
76,4    
Primary school net enrolment 
ratio (%) 2008-2011  
Source: 
[1]http://www.unicef.org/infobycountry/yemen_statistics.html#121 
 
Other factors including not being able to access healthcare, 
and not being able to afford healthcare expenses, parents not 
being too educated and poor access to the basic necessities, 
like water and sanitation are also responsible.   
The most common and serious health conditions Yemen faces 
are diarrhoea, malnutrition, complications of pregnancy, acute 
respiratory infections, and malaria. AIDS is becoming 
increasingly prevalent, and non-communicable conditions 
such as cancer, heart disease and trauma are also on the 
rise[2]. 
Health Care System  
As a proper introduction to the issue at hand, Yemen is an 
Arab country located in the southern Arabian Peninsula with a 
population of 24 million, 70% of whom live in rural areas. 
Yemen divided administratively into 24 governorates and 
Sana’a Capital Trust. Each governorate subdivided into a 
number of districts. The health care services (either public or 
private) are mainly centralized in major cities; though primary 
health units/centers, polyclinics and hospitals are scattered 
throughout the country.  
The health care system consists of a public and a private 
sector. There are three levels of health care. The first level is 
primary health care that focuses on primary health programs 
and provides the first level of care.  Primary health care 
facilities consists of health units, health centers and 
polyclinics. Primary health units commonly have one medical 
assistant or nurse and/or midwife. Primary health care centers 
normally have one or two physicians, nurses, a laboratory and 
some diagnostic facilities. The second health care level is 
secondary health facilities which consist of regional hospitals, 
specialising in curative services.  The third one is the tertiary 
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health facilities which include the national hospitals offering 
specialised care, and they are university-based hospitals. 
The entire healthcare system in Yemen is monitored by the 
Ministry of Public Health and Population (MOPHP) which is 
directly responsible for the health sector and this sector takes 
up the largest percentage of Yemen’s public employees.   As it 
is in most other countries, Yemen does not escape the issues 
of not having adequate number of staff, having to deal with 
poor construction and organisation, poor quality healthcare 
services, not having enough medicines that are deemed 
essential for patients and insufficient issues of budget and 
Government funding.   
It can be safely summarised that the health services in Yemen 
have been outgrown by the exponential population growth.  
With prominent morbidity and mortality from various diseases 
and with high levels of malnutrition prevailing, and the higher 
rates of fertility reported. Therefore, Yemen health care 
system has still a long way to go[3]. 
 
National Policy Issues 
 
A National Health Policy (NHP) does exist in Yemen, and it 
was updated in 2010. Unfortunately the corresponding 
implementation plan does not exist. Similarly, the National 
Medicines Policy (NMP) document also exists in Yemen 
which was updated in 1998[4].  In brief these two policies are 
exist but neither structurally implemented nor regularly 
monitored and evaluated. In general there is no formal 
implementation plan and there are no clear responsibilities.  
In terms of drug distribution for health care purposes, Yemen 
should consider the drawing up of a concrete and updated 
statement of NMP such has been adopted in many other WHO 
member states.  Next, a policy relating to clinical laboratories 
does not exist as well. Access to essential medicines/health 
technologies as part of the fulfilment of the right to health, is 
recognized in the constitution or national legislation but they 
are not fulfilled.  It is unfortunate that there are no official 
written guidelines on medicine donations. It is important to 
establish a well designed, well managed and cost-effective 
supply system with aim of: increasing access to essential 
medicines; maintaining constant supply and minimizing 
medicine losses.        
 
In sum, there is no national good governance policy in Yemen 
and this is probably why Yemen’s MOPHP have to take 
measures to ensure clear-cut guidelines and policy are 
reformulated and re-outlined.  They have to be thorough, 
covering all aspects of healthcare and the guidelines have to 
be delivered efficiently and effectively to the authorities of the 
three levels of the healthcare system in Yemen before they can 
be implemented in different health care facilities, in both the 
public and the private sectors. 
It is worth to mention that the National Health Strategy (NHS) 
2010-2015[5] has stated that: “The Ministry of Public Health 
and Population has exerted some great effort towards 
improving the health conditions for the people through its 
constant attempts to reform the health sector and modernize it. 
The policies and strategies that have been adopted by the 
Ministry since the end of the 1990s were an obvious extension 
of the issues adopted in the First National Conference for 
Health Development in 1994.This strategy hasn't ignored or 
cancelled the accomplishments of the previous strategies but 
rather it was built on their success and is having its priorities 
updated in line with the national, regional and international 
developments bearing in mind the national and local 
characteristics and in consistency with the various economic, 
social, political and geographic conditions”. 
 
Medicines Trade and Production  
The World Trade Organization (WTO) does issue legal 
provisions and grant patents to medicine manufacturers, but 
since Yemen is  new member of this organization  (2014), the 
provision and patent do not exist in the country.  As is the case 
with any agency which should be responsible in managing and 
enforcing Intellectual Property (IP) Rights. Yemen 
Pharmaceutical Country Profile (2006) states that due to this, 
there has been no clear vision about IP Rights since the 
negotiation with international agencies is still in progress.  The 
profile further adds that there are some legal provisions for the 
connection between patent status and marketing authorization, 
there has yet to be a similar provision for data exclusivity for 
pharmaceutcals and patent term extension. Yemen is also 
lagging behind, in terms of initiatives to manage and apply for 
the IP Rights towards promoting public health.  Although the 
tested locally manufactured products have been proven to be 
of good quality, the Yemeni pharmaceutical industry still 
necessitates a great deal of serious attention and improvement 
from various angles, such a production, manufacturing, 
knowledge, attitude and behaviour, policy-making- all 
together to elevate people’s awareness of the nature of 
medicines, the use of medicines, and for the betterment of the 
public’s health status. Thus, on the surface, we can say that the 
medicine trade and production in this country has to be better 
monitored and guided, in order improve the quality, safety and 
efficacy, also to reduce the cost and to curb the adverse effects 
of pharmaceutical products[5]. 
 
Medicine Regulation 
 
In general medicine regulations and legislations aims to ensure 
the quality, safety, efficacy of medicines and accuracy of 
medicine information. It is developed, implemented, 
monitored and re-enforced by Medicine Regulatory Authority 
(MRA). The government of Yemen granted the power of 
responsibility to the MRA.  MRA is responsible for 
registration of medicines; importation, distribution and sales 
of medicines; medicine promotion; licensing of 
pharmaceutical establishments, their staff and performance; 
pharmaceutical quality assurance; commitment to Good 
Manufacturing Practice (GMP) and regulation enforcement. 
The SBDMA is the main MRA in the country. It is a semi-
autonomous agency concerned mainly with authorizing 
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marketing, importing and manufacturing control; providing 
licenses for medicines, medicine producers and wholesalers; 
controlling the medicine market and controlling the quality 
and pharmacovigilance of the imported medicines and medical 
appliances.  
  
In the last five years, the medicines regulatory system has 
been placed under proper assessment.  The SBDMA receives 
funding from the government budget but it also retains its 
revenues from regulatory activities.   
In Yemen, marketing authorization for all pharmaceutical 
products is required.  Since mutual recognition mechanisms do 
not seem to be available, publicly available criteria have been 
adopted to assess applications for marketing authorization of 
the products. Yemen Pharmaceutical Profile, 2006 states that 
there were  9,500 pharmaceutical products registered in  
Yemen in 2007 . However, one weakness that is apparent is 
that the MRA fails to distribute a list of the registered 
products, updating the names of the products on a regular 
basis, in order to know about the authorized products that that 
are officially available in the country.  The Profile further 
reveals that there is a guide for the registered pharmaceuticals 
but it has not been updated for more than a decade.   
Registration and authorization should have made the public 
feel ‘safe’ about using the medicines that are suitable to their 
health complications and needs, but the seemingly 
lackadaisical attitude of the authority regarding updating the 
medicines and pharmaceuticals marketed have created 
loopholes in the healthcare system in Yemen.  Similarly, even 
though legal provisions exist to allow the appointment of 
government pharmaceutical inspectors and to allow them to 
check premises in which pharmaceutical activities are 
performed, local manufacturers, private wholesalers and retail 
distributors have claimed that inspections have been 
infrequent and there has been suggestions of contradiction 
between the responsibilities of the MRA and those 
accountable for the pharmaceutical affairs in the MOPHP.  
 
Medicine Financing 
 
As has been seen earlier, Yemen is a country challenged with 
limited economic and social development. Its health indicators 
are some of the lowest globally, and improving them is very 
difficult battle.  In 1995, the Government launched an 
economic reform program with support from the World Bank 
and the International Monetary Fund (IMF). The Government 
revenues are 37.7 per cent of Gross Domestic Product (GDP), 
over 68 per cent from oil, 24 percent from taxes, and the 
remainder from other sources[5]. The external debt to GDP 
ratio is 74.9 per cent (before rescheduling) and gross official 
reserves account for about 4 months of imports Another 
challenge to the Government’s efforts to strengthen its 
economy came in 1998 following a dramatic drop in oil prices. 
The resulting 15 per cent across-the-board cut in the public 
sector budget, further tightened scarce resources for the health 
sector.  As a result, public spending on health is currently 
about 2 per cent of GDP and 4.8 per cent of total government 
expenditure - the lowest per capita health spending in the 
region.[5] Limited public resources and poor health indicators 
are catalysts for rethinking of the health strategy by the 
MOPH in partnership with the World Bank and other key 
donors. 
Potential sources of funds for public pharmaceutical 
procurement include government financing, user fees, health 
insurance, community co-financing for health facility visit, 
diagnosis and treatment, and donor financing. These options 
vary in terms of their efficiency, equity and sustainability. The 
most important considerations for public procurement are total 
funds available, adequate access to foreign exchange and the 
regularity with which funds are available. It is the 
responsibility of government, policy makers and senior 
managers to establish appropriate and reliable funding for 
public drug procurement as a high priority, and to implement 
mechanisms which provide adequate funding on time to 
support public sector procurement. 
Looking specifically into Yemen, there are six major sources 
of funds for government health spending: 
1. The central MOPHP budget; 
2. Foreign assistance; 
3. Governorate health budgets; (there is a small budget 
allocated to each governorate to cover some of their 
health expenses) 
4. The Social Fund for Development (provided by the 
Prime Minister’s Office); 
5. The Public Works Project (under the Ministry of 
Planning & Development); and  
6. The Ministry of Finance, which directly funds the 
central MOPHP budget, the governorate budgets, as 
well as Al-Kuwait and Al-Thawra Hospitals in Sana’a 
and the SBDMA (institutional budget). 
It is important to increase government funding for priority 
diseases, poor people and disadvantages to improve the 
availability and accessibility of safe and effective essential 
medicines. 
Pharmaceutical procurement and distribution in the 
public sector  
The local pharmaceutical industry covers approximately 10–
20 per cent of the total market[6]. Yemen is a member of the 
Arab Union of the Manufacturers of Pharmaceuticals and 
Medical Appliances, and ranks 11th among Arabic countries in 
medicine production.Yemen spends about US$263 million a 
year on pharmaceutical products, according to the SBDMA[6]. 
Most of this expenditure is spent on importing medicines from 
50  countries through 400 licensed importers, as local 
pharmaceutical plants produce only 10–20 per cent of 
Yemen’s requirements.  There are about 500 foreign 
pharmaceutical companies and more than 13,000 brand and 
generic medicines registered in Yemen. In 2012, the MOPHP 
and the SBDMA started a new policy to ensure the quality of 
medicines in Yemen[5].  
In 1964, the Yemeni government initiated a joint venture with 
private investors in establishing the Yemen Drug Company 
(YEDCO). This company started in marketing pharmaceutical 
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products. The company imported drugs from foreign 
companies and marketed and distributed them in local 
pharmacies and drug stores.  A few decades down the line, 
YEDCO took a step forward by starting its first 
pharmaceutical factory in Sana’a for producing 
pharmaceutical products.  The second pharmaceutical 
company, Shibapharma was established in Sana’a 29 years 
after the Yemen Drug Company.  ShibaPharma products are 
sold in Yemen and even exported to Middle Eastern and 
African countries.   
We had mentioned earlier in this paper that the dispensers in 
pharmacies are mostlynot pharmacists, and a journal has 
revealed that a few pharmacies even use the old versions of 
the British National Formulary (BNF) or the East Medical 
Index[7].This implies, that poor quality and out-of-date drug 
information resources in pharmacies can affect the quality of 
the information provided to patients and prescribers, and the 
consumers will not be updated regarding new information on 
pharmaceutical drugs they are purchasing.    
  
In a manual of the World Health Organization (1999) entitled 
“Operational Principles for Good Pharmaceutical 
Procurement”, it has been mentioned pharmaceutical 
procurement is a complex process involving many steps, 
agencies, ministries and manufacturers[8]. Existing 
government policies, rules and regulations for procurement as 
well as institutional structures are frequently inadequate and 
sometimes hinder overall efficiency in responding to the 
modern pharmaceutical market.  There are many steps in the 
procurement process. No matter what model is used to manage 
the procurement and distribution system, efficient procedures 
should be in place: to select the most cost-effective essential 
drugs to treat commonly  encountered diseases; to quantify the 
needs; to pre-select potential suppliers; to manage 
procurement and delivery; to ensure good product quality; and 
to monitor the performance of suppliers and the procurement 
system. Failure in any of these areas leads to lack of access to 
appropriate drugs and to waste of  resources. In many public 
supply systems, breakdowns regularly occur at multiple points 
in this process. 
 
In Yemen, drugs supplied to the public sector are procured 
through international tender and rarely by limited competitive 
tender or local purchase from local agents. Procurement is 
based on the prequalification of suppliers. Public sector 
procurement in Yemen is both centralized and 
decentralized.The government supply system department in 
Yemen has a Central Medical Stores at the national level in 
Sana’a Capital Trustwhich, also known as Sana’a central 
medical stores. There are another 4 regional public 
warehouses responsible for storage and distribution of  
medicines, medical appliances and medical supplies. Each 
regional store stores and distributes medicines, medical 
supplies and medical appliances to the public(MOPHP) stores 
in a number of governorates which are located near to it. The 
governorate main stores distributes medicines, medical 
appliances and medical supplies to the MOPHP health 
facilities in the governorate. There are 95 national guidelines 
on Good Distribution Practices.In Yemen a licensing authority 
that issues Good Distribution Practices licenses does not exist, 
notwithstanding.  
It is important to ensure that selected and procured medicines 
are necessary for health care of the nation, available to 
communities and individuals and can be safely and effectively 
used. 
 
Selection and rational use of medicines 
In Yemen many papers and documentation, regarding to 
pharmaceutical regulation and procurement are commonly 
exist and yet when it comes to the implementation, updating 
the policies and information the scenario is poor.  The 
National Essential Medicines List (NEML), for instance was 
last updated in 2009 [4]and we are sure that a lot of the 
medicines would have been reexamined and revised since 
then. 
However, the last alignment between the List and the Standard 
Treatment Guidelines (STG) was reported in 2010.  There is 
no public or independently funded national medicines 
information center functioning to provide medicinal 
information or findings to prescribers, dispensers or 
consumers.  Public education campaigns are also lacking. For 
the past two years, there have been no campaigns aiming to 
educate the public on using medicines rationally.  Not only 
that, surveys which might be another medium of information 
to the public at large have also not been conducted.  No 
national program, or committee, seeking to monitor and 
promote rational use of medicines seems to be under 
consideration by the MOPHP.   
It is equally disappointing that Yemen has no regulations 
which necessitate hospitals to organize/develop committees 
concerned with Drug and Therapeutics, and subsequently 
adherence to STG is also does not exist, or in some cases, 
have become obsolete.   
For physicians, nurses, medical assistants and other health 
staff, pharmaceutical issues are not detailed and explained to 
them as a part of continuing education.  Even if continuing 
education is mandatory, pharmaceutical concerns have sadly 
been underestimated and are not included.   
This brings us to the next issue- pharmacovigilance.  
Pharmacovigilance is defined by the World Health 
Organization(WHO) as the science and activities related to the 
detection, assessment, understanding and prevention of 
adverse effects or any possible drug-related issues.  Drug 
regulatory mechanisms were strengthened following the 1961 
tragedy involving thalidomide [9].  One thing that had 
seemingly escaped the awareness of the people at the time was 
how prescribing drugs for off-label purposes or in simple 
words, for purposes other than those intended and prescribed 
for, was (and still is) a common practice in a lot of countries 
today.  Little did they know then that some drugs can cause 
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adverse reactions which are sometimes severe and even 
detrimental and fatal.  In 1961, it occurred to the physician 
who had first introduced thalidomide to his pregnant patients 
that it was the same product that might have caused severe 
birth defects in the babies he himself had delivered. In fact, the 
drug interfered with the babies’ normal development, causing 
them to be born with phocomelia, resulting in shortened, 
absent or disfigured limbs.  Through confirmation of the 
effects it had on the babies, the drug was banned in most 
countries.  
In Yemen, the monitoring of adverse drug reactions was 
started by the establishment of a pharmacovigilance centre in 
2011 by the SBDMA[2]. So far there is no published 
information about its work, number of reports and how they 
are processed.  In addition problems related to drug 
smuggling, counterfeit drugs, improper and irrational use of 
drugs, importation of unnecessary drugs and medical errors 
are widely existed.  
 Academics from the Faculty of Pharmacy at Aden University 
decided recently, with responsible officers from SBDMA in 
Aden, to initiate a pharmacovigilance programme in Yemen, 
to exapnd the pharmacovigilance centre of SBDMA to cover 
the whole country and implement the basic steps for 
establishing pharmacovigilance nationwide. 
Considering the fact that the public is not fully aware of the 
risks of medicines and the possiibility of their misuse and 
abuse, the govenment of Yemen has decided to dispense drugs 
only by prescriptions except some medicines which can be 
dispensed without prescriptions namely over-the counter 
(OTC) medicines. However, The MOPHP and the Supreme 
Board of Drugs and Medical Appliances (SPDMA) fail to 
regulate, control, and monitor the prescriptions. In general, 
people in Yemen may not have been very well informed about 
the potential effects of drugs and dispensing medication 
without a valid prescription is common in this country. All 
medicines including prescribing-only medicines (POM) such 
as antibiotics, antipsychotic, cardiovascular drugs can be 
obtained without a prescription from pharmacies.  Pharmacies 
are mostly run by pharmacy technicians and untrained 
dispensers, in addition to few qualified pharmacists. Thus we 
cannot expect that the pharmacy staff would know the detailed 
impact of a drug they sell to customers.  It is common place in 
Yemen, that these dispensers are regarded as ‘physicians’ so 
in many times they do diagnosis, prescribing and dispensing 
medicines for various health complications and diseases, 
despite their non-existent knowledge and authority. 
 
Rational use of medicines aims to improve the use of 
medicines by health providers, individuals and community 
through rational prescribing, dispensing and appropriate use of 
individuals and community. 
 
Future Challenges 
Having looked into the demographic and the current 
pharmaceutical states of Yemen, its health system and 
services, pharmaceutical policies, trade and production, 
regulations, financing, pharmaceutical product procurement 
and distribution, and finally down to the laymen, their 
knowledge, attitude, and practice, also the poor handling of 
information and updates, we can predict a number of future 
challenges.   
First of all, the authorities need to be educated about the 
importance of updating the policy and information resources 
on pharmaceutical products that will be sold, or are already 
sold at the counter. This is the greatest challenge to overcome.  
The second challenge is to reform the pharmacy curriculum 
taught in the public and private universities and institutes and 
to educate the community pharmacies and drug stores owners 
and employers.  This is because the importance of formal and 
continuing education and to increase the awareness as it is 
common to dispense any medicine without prescription in 
Yemen .  Also they have to know that their role is not just 
dispensing but also to educate the patients and consumers 
about the drugs they are dispensing.   
Another challenge is that the numbers of physicians have 
outnumbered the clinical pharmacies in the country.  Thus, 
there is a need for the MOPHP to build more pharmacies, 
especially in Yemeni hospitals. As the top people are informed 
and educated about the importance of pharmacovigilance 
through a number of campaigns, workshops, talks, or through 
reading materials, the public also needs to be informed and 
made aware of the importance of being treated and diagnosed 
by qualified physicians, rather than depending on the 
‘diagnosis’ of staff working at the pharmacies.   
There is also a challenge in identifying and confiscating 
counterfeit drugs in Yemen.  Therefore, drug policing needs to 
be made stricter and the MOPHP must prepare a guideline on 
the types of drugs that are sold in the market.  The healthcare 
professionals and the public must be informed of the existence 
of these counterfeit drugs and to be able to distinguish 
between drugs that are ‘valid’ and drugs counterfeited.   
Next, Yemen has to think of ways to address the problem of 
curbing the number of pharmacies and drug stores operated by 
unqualified persons.  This non-qualification issue has 
contributed to the fact that pharmacy practice has been 
undermined in Yemen, both in terms of recognition from the 
Ministry of Higher Education and in terms of the general 
perception of the state of the profession in Yemen.    
Conclusion 
Despite the progress Yemen has made with regard to 
expanding and improving its health care system over the past 
decade, the system remains severely underdeveloped.  To 
improve pharmacy practice in Yemen, many changes are 
crucial, including updating the pharmacy curriculum taught, 
implementing standards for pharmacy practice, implementing 
and/or reinforcing pharmacy legislations and regulations, as 
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well as integrating pharmacists more comprehensively in the 
healthcare system as a member of the health care team. 
Additionally, the quality of the pharmacy workforce needs 
improvement, and awareness needs to be increased among the 
public, physicians, other healthcare professionals, and policy 
makers about the value of pharmacists as health professionals. 
Everyone, from the MOPHP, the policy makers, to healthcare 
professionals and the community have to be educated about 
pharmacovigilance, the adverse effect of drugs and the danger 
of being exposed to them. This is not an easy task, but can 
help the Government address the different pharmaceutical-
related challenges and transform Yemen’s healthcare system.   
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